CytoPherx, Inc.

Pioneering medical advancements to combat inflammation-based diseases with innovative selective cytopheresis systems.

General Information
Company Name
CytoPherx, Inc.
Founded Year
2007
Location (Offices)
Ann Arbor, United States +1
Founders / Decision Makers
Jim Danehy - CEO & President Marlene Moore - Manager Charles Fisher - Executive Chairman & CEO
Number of Employees
2
Industries
Health Care, Life Sciences, Medical Devices
Funding Stage
Series C
Social Media

CytoPherx, Inc. - Company Profile

CytoPherx is a healthcare startup founded in 2007 and headquartered in the United States. The company is pioneering medical advancements to combat inflammation-based diseases with innovative selective cytopheresis systems. Formerly known as Nephrion, CytoPherx is a clinical-stage medical device company that focuses on diseases and conditions driven by inflammation. Their products are customized configurations of a proprietary system designed to modulate inflammation through selective cytopheresis. CytoPherx secured a significant $34.00M Series C investment on 04 January 2012, with contributions from a consortium of notable investors including Capital Midwest Fund, Early Stage Partners, Kaiser Permanente Ventures, Emergent Medical Partners, Onset Ventures, Aphelion Capital, Apjohn Ventures, Charter Oak Equity, North Coast Technology Investors, and the Lurie Investment Fund.

Taxonomy: medical device, clinical-stage, cytopheresis, inflammation, diseases, selective cytopheresis, medical advancement, innovation, inflammation-based diseases, inflammatory conditions, proprietary system, modulating inflammation, biomedical engineering

Funding Rounds & Investors of CytoPherx, Inc. (4)

View All
Funding Stage Amount No. Investors Investors Date
Series C $34.00M 10
Capital Midwest Fund, investor in CytoPherx, Inc.'s Series C round Early Stage Partners, investor in CytoPherx, Inc.'s Series C round Kaiser Permanente Ventures, investor in CytoPherx, Inc.'s Series C round Emergent Medical Partners, investor in CytoPherx, Inc.'s Series C round Onset Ventures, investor in CytoPherx, Inc.'s Series C round Aphelion Capital, investor in CytoPherx, Inc.'s Series C round Apjohn Ventures, investor in CytoPherx, Inc.'s Series C round Charter Oak Equity, investor in CytoPherx, Inc.'s Series C round North Coast Technology Investors, investor in CytoPherx, Inc.'s Series C round
Lurie Investment Fund 		04 Jan 2012
Series B $11.70M - 17 Jun 2010
Debt Financing $2.00M - 06 Nov 2009
Series A $2.50M - 22 Oct 2007

Latest News of CytoPherx, Inc.

View All

No recent news or press coverage available for CytoPherx, Inc..

Similar Companies to CytoPherx, Inc.

View All
BioAegis Therapeutics, Inc. - Similar company to CytoPherx, Inc.
BioAegis Therapeutics, Inc. Commercializing a key component of the immune system, #Gelsolin, for infectious, inflammatory and degenerative diseases.
Danking Pharmaceuticals - Similar company to CytoPherx, Inc.
Danking Pharmaceuticals Pioneering advancements in oncology and therapeutic research for cancer, inflammation, blood, and metabolic diseases.
Xalud Therapeutics, Inc. - Similar company to CytoPherx, Inc.
Xalud Therapeutics, Inc. We seek to address the significant unmet need for safe and efficient treatments for chronic pain-related diseases.
Sepsia Therapeutics - Similar company to CytoPherx, Inc.
Sepsia Therapeutics Pioneering innovative broad-spectrum drug and cellular therapies to combat sepsis by targeting infection-induced inflammatory responses.
Better Vision Center - Similar company to CytoPherx, Inc.
Better Vision Center Enhancing vision with comprehensive eye care and specialized treatments for a range of ocular conditions.
Circle Decoration Circle Decoration

Want to dive deeper into CytoPherx, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now